Disease oriented network
CZECRIN | ONCO
An industry-oriented network linking clinical sites, researchers and experts focused on the diagnosis, treatment and prevention of solid tumours.
Mission CZECRIN | ONCO
The mission of the Cancer DONET is to become a connecting platform for patient-centered clinical research in solid tumors – a place where science truly helps patients through the use of real-world data, innovative study design, and shared expertise.
Vision CZECRIN | ONCO
- Establishment and support of a network of clinical and academic centres collaborating in the field of solid tumour research
- Supporting independent clinical trials reflecting the needs of clinical practice and patients
- Providing expert and methodological support in the field of clinical trial design, regulation, data management, monitoring, pharmacovigilance, etc.
- Use of real-world data (RWD) and creation of real-world evidence (RWE)
- Strengthening international cooperation
CZECRIN | ONCO is an industry-oriented network
which aims to support the design, implementation and development of academic clinical trials in this area – from protocol design to the implementation of results into clinical practice. It was established in 2020 to systematically support academic clinical research in the field of solid tumours. It responds to the specific patient needs and challenges of this rapidly evolving field.
The CZECRIN | ONCO network connects cancer centres, research teams and clinical experts who want to actively participate in academic and sponsored clinical trials in the field of oncology. If you are interested in collaborating or joining the network, please fill out the following form.
Connected centres in the CZECRIN DONET network | ONCO
The DONET network CZECRIN | ONCO includes sites across the Czech Republic that share know-how, coordinate research activities and contribute to strengthening the quality of independent studies in the field. All centres collaborate on the GENESIS project .
Fakultní nemocnice u sv. Anny v Brně
Centre for Clinical Studies St. Anne’s Hospital in Brno is an important partner for CZECRIN, providing complete support for clinical trials in the hospital. It coordinates all processes, communicates with sponsors of commercial studies and participates in the implementation of academic projects. At the same time, it acts as a point of contact for patients and volunteers. The centre assists with the preparation of documentation for regulatory authorities, contracting with partner centres and monitoring studies, thus ensuring the quality and safe conduct of clinical trials.
St. Anne’s University Hospital in Brno – homepage | FNUSA
Centre for Clinical Studies | FNUSA
MUDr. Jana Katolická, Ph.D.
Head of the Oncology and Surgery Department
St. Anne’s University Hospital in Brno
Masaryk Institute of Oncology
The Masaryk Institute of Oncology (MOÚ) is a key partner of the CZECRIN network. It is home to the first Centre for Precision Oncology in the Czech Republic, which in cooperation with CZECRIN established the GENESIS project. This national platform aims to unify procedures, share data and analyse the effectiveness of modern targeted therapies across the Czech Republic. The Centre is also actively involved in recruiting patients for clinical trials.
You can read more about precision oncology here.
University Hospital Brno
The Clinical Trials Department of the Brno University Hospital, which falls under the Office of the Deputy Minister for Science and Research, provides administrative support for clinical trials across the hospital’s clinics. The team prepares contracts and budgets with sponsors, controls payments, keeps records of studies and prepares documents for invoicing and cost accounting. Support includes the involvement of OKS study coordinators in specific projects and coordination of the contract negotiation process in collaboration with the Legal Affairs Department. The Unit also manages the CTIS identifiers of the various departments and provides contact support for the contracting authorities and partner centres.
Department of Clinical Studies – University Hospital Brno
MUDr. Michal Eid
Doctor of the Internal Hematology and Oncology Clinic
University Hospital Brno
University Hospital Ostrava
The Clinical Trials Centre of the Ostrava University Hospital is a key place for initiating and coordinating clinical trials in the hospital. It serves as a link between study sponsors and investigators, ensuring fast, accurate and efficient communication. It enters the process as an administrative, financial and control authority and no clinical trial can be implemented at FNO without its approval. Its main objective is to simplify and speed up all processes related to the conduct of studies. Since 2016, FN Ostrava has been part of the national research infrastructure CZECRIN, which supports academic clinical trials and operates in connection with the European ECRIN network.
Centre for Clinical Studies (CKS) | University Hospital Ostrava
doc. MUDr. Ing. Jakub Cvek, Ph.D.
Head of the Oncology Clinic
University Hospital Ostrava
University Hospital Hradec Králové
The Hradec Králové University Hospital offers its partners comprehensive cooperation in the field of clinical evaluation of drugs and medical devices, which it provides at the level of a top medical facility with modern equipment and experienced experts. In recent years, the interest in the implementation of studies has been growing significantly, especially in the fields of oncology, hematology and neurology, but the hospital has long been a reliable partner in internal medicine and surgery. Clinical trials are conducted in accordance with Czech legislation, international standards and ethical principles. In order to start a study, it is necessary to submit complete documentation: from the application and protocol through the approval of the SÚKL and the ethics committee to the draft contract with economic calculation and related manuals and forms.
Clinical evaluation of medicines | University Hospital Hradec Králové
doc. MUDr. Milan Vošmik, Ph.D.
Head of the Department of Oncology and Radiotherapy
Hradec Králové University Hospital
Thomayer University Hospital
Thomayer University Hospital is an active member of the national and European infrastructure CZECRIN, which supports academic clinical research and connects Czech institutions with international projects through the ECRIN-ERIC network. CZECRIN brings together key clinical centres, offers expert capacities for research and development of drugs and medical devices and sets quality standards for processes and data in accordance with FAIR principles. At the same time, it is dedicated to education and competence development in the field of clinical trials, thus strengthening the professional background for the implementation of academic trials throughout the Czech Republic.
Clinical research | Fakultní Thomayerova nemocnice
doc. MUDr. Radka Lohynská, Ph.D.
Head of the Oncology Clinic
Thomayer University Hospital
Motol University Hospital
The Clinical Trials Department of Motol Hospital provides administrative support for commercial and academic studies conducted at the hospital and works closely with CZECRIN. The Motol Hospital is the venue for clinical trials of drugs and medical devices and academic clinical trials, where the team provides support from submission to the SÚKL and ethics committees, through the preparation of synopses and informed consents to the conclusion of contracts with partner centres and monitoring of studies.
Clinical evaluation at Motol University Hospital – Motol University Hospital
prof. MUDr. Tomáš Büchler, Ph.D.
Head of the Oncology Clinic
University Hospital in Motol
doc. MUDr. Kateřina Kopečková, Ph.D.
Doctor, Oncology Clinic
Motol University Hospital
General University Hospital
The Clinical Trials and Research Department of the VFN provides comprehensive administrative and professional support in the initiation and implementation of clinical trials. It provides communication with sponsors and CROs, coordinates the start-up phase including legal and economic review of contracts, and links clinics with sites such as laboratories, pharmacy and imaging. It also supports investigator-initiated academic projects (IITs), assists staff with preparation of documents, study billing, payment control and record keeping. The department participates in inspections and audits, coordinates the archiving of documentation, and ensures the payment of travel reimbursements to patients.
Clinical Evaluation and Research – General University Hospital in Prague
doc. MUDr. Michal Vočka, Ph.D.
Head of the Oncology Clinic
General University Hospital in Prague
University Hospital Pilsen
The University Hospital Plzeň has long been involved in the implementation of clinical trials across a wide spectrum of medical disciplines. As a modern teaching facility with highly specialised facilities, it is involved in both commercial and academic projects and provides the expertise of doctors, study coordinators and specialised departments. Clinical trials are conducted in accordance with current legislation and international standards, with an emphasis on patient safety and the quality of the data obtained. FN Plzeň is dedicated to the development of new drugs and medical devices, as well as to supporting research activities within the national infrastructure CZECRIN and involves hundreds of patients in studies that contribute to the development of modern medicine.
University Hospital Olomouc
Olomouc University Hospital is actively involved in conducting clinical trials of drugs and medical devices across specialist departments. As a modern university centre, it offers the facilities of top clinics, experienced teams of investigators and high-quality technical equipment. Studies are conducted in accordance with national legislation, international standards and ethical principles with an emphasis on patient safety and accuracy of the data obtained. The hospital cooperates with sponsors in the preparation of documentation and contracts and provides expert support throughout the duration of the clinical trial.
Clinical evaluation of medicines and medical devices | University Hospital Olomouc
prof. MUDr. Bohuslav Melichar, Ph.D.
Head of the Oncology Clinic
University Hospital Olomouc
Královské Vinohrady University Hospital
The Department of the Deputy Director for Science and Research at the Královské Vinohrady Hospital provides comprehensive management of the scientific and research agenda across the hospital. It coordinates the development of science in clinical and laboratory departments, methodically leads research activities and supports the introduction of the most modern treatment procedures. At the same time, it is involved in the preparation and coordination of grant projects at national and international level, ensures the implementation and cooperation in clinical trials and oversees the effective use of funds resulting from the status of a research organisation. The department also includes an Ethics Committee and an Office for International Cooperation in Science and Research.
Královské Vinohrady University Hospital
prof. MUDr. Renata Soumarová, Ph.D., MBA
Head of the Oncology Clinic
Královské Vinohrady University Hospital
List of workplaces by region
Capital City of Prague
FN in Motol, Thomayer University Hospital, General University Hospital in Prague, FN Královské Vinohrady
Pilsen Region
FN Pilsen
Hradec Kralove Region
FN Hradec Králové
South Moravian Region
St. Anne’s Hospital in Brno , FN Brno, Masaryk Institute of Oncology
Olomouc Region
FN Olomouc
Moravian-Silesian Region
FN Ostrava
Organisational structure
CZECRIN | ONCO, as a national network dedicated to supporting clinical research in the field of solid tumour oncology, has a governance structure that ensures transparent and efficient operation. The network operates under the auspices of the national research infrastructure CZECRIN.
All participating institutions and partners have the opportunity to actively participate in shaping the research direction of the CZECRIN | ONCO network and thus contribute to the development of modern cancer care and increasing its availability and quality for patients in the Czech Republic.
Leading Investigator
doc. MUDr. Radka Lordick Obermannová, Ph.D.
Leading Investigator
Doc. MUDr. Radka Lordick Obermannová, Ph.D. works as a consultant in the field of clinical oncology at the Department of Complex Oncological Care at the Masaryk Cancer Institute in Brno. She specializes in the treatment of patients with tumors of the gastrointestinal tract. She graduated from the Faculty of Medicine of Masaryk University in Brno, where she completed her specialisation training in clinical oncology and postgraduate doctoral studies. Her scientific focus on gastrointestinal cancers has shaped her research career, particularly her interest in optimizing multimodal treatment of esophageal cancer and identifying predictors of treatment response.
Since 2012, she has been the lead physician of the Phase I Unit and is actively involved in the development of new drugs as a principal investigator and co-investigator of Phase I-III clinical trials. Since 2025 she has been the Head of the Clinical Trials Unit at Masaryk Cancer Institute.
Doc. Lordick Obermann is the author of the national recommendations for the treatment of oesophageal and gastric cancer and co-author of the European ESMO recommendations for the treatment of oesophageal cancer. She is an active member of the ESMO Faculty Group on Non-Colorectal Gastrointestinal Cancer and participates in the leadership of the EORTC Gastric Cancer Working Group. She is also a member of the International Gastric Cancer Association (IGCA) and the Czech Cancer Society.
Branch Council
The specialty council is a professional platform of the specialty network, which aims to define research priorities in oncology. It focuses on promoting high quality research projects – from identifying topics with high clinical and scientific merit to reviewing proposals for national and international studies.
Members of the specialty board are experienced representatives of the academic and clinical spheres. The implementation of relevant outputs of clinical trials into practice, e.g. by redefining recommended practices, is ensured by close links with the professional society, whose representatives are often also members of the Board.
The branch council thus creates an autonomous professional framework for the strategic direction and development of research activities within the branch network.
prof. MUDr. Tomáš Büchler, Ph.D.
Head of the Oncology Clinic
University Hospital in Motol
doc. MUDr. Ing. Jakub Cvek, Ph.D.
Head of the Oncology Clinic
University Hospital Ostrava
MUDr. Michal Eid
Doctor of the Internal Hematology and Oncology Clinic
University Hospital Brno
prof. MUDr. Jindřich Fínek, Ph.D.
Head of the Oncology and Radiotherapy Clinic
University Hospital Pilsen
MUDr. Jana Katolická, Ph.D.
Head of the Oncology and Surgery Department
St. Anne’s University Hospital in Brno
doc. MUDr. Kateřina Kopečková, Ph.D.
Doctor, Oncology Clinic
University Hospital in Motol
doc. MUDr. Radka Lohynská, Ph.D.
Head of the Oncology Clinic
Thomayer University Hospital
prof. MUDr. Bohuslav Melichar, Ph.D.
Head of the Oncology Clinic
University Hospital Olomouc
doc. MUDr. Michal Vočka, Ph.D.
Head of the Oncology Clinic
General University Hospital in Prague
prof. MUDr. Renata Soumarová, Ph.D., MBA
Head of the Oncology Clinic
Královské Vinohrady University Hospital
doc. MUDr. Milan Vošmik, Ph.D.
Head of the Department of Oncology and Radiotherapy
University Hospital Hradec Králové
Members
The members of the CZECRIN | ONCO network represent an active professional community that connects academic and clinical institutions involved in cancer research in the Czech Republic. Unlike the members of the disciplinary council, who are dedicated to the strategic and conceptual direction of research, the members of the network focus primarily on the practical implementation of clinical trials – from protocol design and centre involvement to data collection and sharing of results.
Their activities are crucial for the transfer of scientific knowledge into clinical practice, the development of collaboration between centres and the strengthening of academic research infrastructure in oncology. CZECRIN | ONCO members also act as ambassadors of the network in their institutions and contribute to the development of academic clinical research and the visibility of the Czech oncology community in the international context.
The CZECRIN | ONCO network consists of experts from all over the Czech Republic who are involved in the development of academic clinical research in oncology.
Their common goal is to link research with clinical practice and to support the implementation of national and international clinical trials.
Project Management
Mgr. Martina Lojová, Ph.D.
Project Manager CZECRIN | ONCO
martina.lojova@mou.cz
543 13 6232
Collaboration
CZECRIN | ONCO creates a space where clinical research, diagnostics and clinical care are linked through the support and development of academic clinical trials in the Czech Republic.
The platform provides a methodological, coordinating and organizational background for collaboration between research teams, clinical sites and diagnostic centres. It supports data sharing, process harmonisation and patient involvement in research activities in line with clinical research principles, including in the field of personalised medicine.
CZECRIN | ONCO thus creates an interconnected infrastructure that strengthens clinical research, enables efficient transfer of knowledge into practice and supports the implementation of innovative approaches in oncology.
Centre for Precision Oncology
The Centre of Precision Oncology of the Masaryk Cancer Institute (MOÚ) is a professional and technological base for molecular genetic testing of solid tumours in patients from the Czech Republic.
It has state-of-the-art facilities for molecular diagnostics and bioinformatics and provides:
- molecular diagnostics and sequencing,
- bioinformatics analysis and data interpretation,
that form the basis of a personalised approach to the treatment of solid tumours.
The Centre for Precision Oncology cooperates closely with the University Hospital Brno, both with the Internal Hematology and Oncology Clinic and the Clinic of Paediatric Oncology.
Project GENESIS Czech Republic
The GENESIS project establishes the framework of the Czech National Molecular Tumour Board Platform and the Czech National Precision Medicine Network, which connect diagnostic, research and clinical teams across the country.
GENESIS thus provides a comprehensive source of clinical and molecular data that is useful for both scientific research and practical clinical decision support.
The Centre for Precision Oncology is an expert partner of the GENESIS project and provides its technological, bioinformatics and analytical background.
Together they contribute to the development of data-driven personalised oncology in the Czech Republic.
Molecular Tumor Board
The Molecular Tumor Board (MTB) is a multidisciplinary expert forum that clinically interprets data from the Precision Oncology Center and the GENESIS project and translates it into treatment decision-making.
It brings together clinical oncologists, pathologists and molecular biologists, geneticists, bioinformaticians, pharmacologists and other experts who:
- assess individual treatment options,
- recommend targeted therapy or an appropriate clinical trial,
- ensure the transfer of research findings into clinical practice, i.e. real oncological care for patients with solid tumours.
MTB thus represents a key bridge between laboratory diagnostics and clinical decision-making.
Clinical trials and research projects
CZECRIN | ONCO collaborates on clinically relevant projects focused on the diagnosis, treatment and prevention of solid tumours, while supporting education and the development of the research environment in its field. Our goal is to ensure that patients with solid tumors have access to personalized and innovative diagnostics, treatment and prevention through well-designed and implemented academic clinical trials.
Ongoing clinical trials
Name
- GastroPET II; Sequential FDG-PET and miRNA as a biomarker of change in preoperative treatment strategy in locally advanced gastric and gastroesophageal junction cancer – a follow-up study
Design
- Non-interventional academic clinical follow-up study
Diagnosis
- Patients with locally advanced resectable adenocarcinoma of the oesophagus and stomach (Siewert I – III) with T3N0, T4N0, T2 – T4N+, stage Ib – IIIc with indication for FOLFOX or FLOT treatment previously enrolled in KH GastroPET
Description
- The aim of this follow-up study is non-interventional follow-up of the secondary endpoints of KH LP GastroPET in the population of enrolled patients, namely the predictive values of PET for disease free survival (DFS) and overall survival (OS) in individual arms defined by the KH LP GastroPET protocol.
Contact
- Contracting authority: the Masaryk Institute of Oncology
- Leading Investigator: doc. MUDr. Radka Lordick Obermannová, Ph.D.
Centres in the Czech Republic
- Masaryk Institute of Oncology; PI: doc. MUDr. Radka Lordick Obermannová, Ph.D.
- General University Hospital in Prague; PI: doc. MUDr. Milada Zemanová, Ph.D.
- University Hospital Olomouc; PI: doc. MUDr. Hana Studentová, Ph.D.
Name
- GENESIS, Genomic Alterations Platform for Next Clinical Studies
National e-platform for molecular tumor boards
Status
- Active recruitment
Description
- Genesis is a multicentre project of a consortium of ten clinical oncology centres with an active molercular tumour board in the Czech Republic. The project is an integral part of an innovative approach to the treatment of malignant diseases, called precision oncology, which adapts therapy to the individual characteristics of the patient and his tumour.
Objectives
- harmonisation of indications for genomic testing,
- harmonization of individual molecular tumor board outputs,
- Data collection and sharing, analysis of the effectiveness of molecularly-genomically targeted therapies,
- cost-effectiveness analyses of different treatment approaches, etc.
International cooperation and partnerships
- PRIME ROSE (PRecisIon Cancer MEdicine RepurpOsing SystEm Using Pragmatic Clinical Trials)
- EMTBN(European Molecular Tumour Board Network),
- University of Oslo, Norway
- West Cancer Center, Memphis, USA
- CCC Munich – comprehensive cancer centre, Munich, Germany
Contact
- Contracting authority: the Masaryk Institute of Oncology
- Leading Investigator: doc. MUDr. Radka Lordick Obermannová, Ph.D.
Centres in the Czech Republic
- Motol University Hospital; PI: doc. MUDr. Kateřina Kopečková, Ph.D.
- Thomayer University Hospital; PI:doc. MUDr. Radka Lohynská, Ph.D.; doc. MUDr. Ludmila Boublíková, Ph.D.
- General University Hospital in Prague; PI: doc. MUDr. Michal Vočka, Ph.D.; MUDr. Ludmila Křížová
- University Hospital Královské Vinohrady; PI: prof. MUDr. Renata Soumarová, Ph.D., MBA; MUDr. Emma Šlopková
- Hospital České Budějovice; PI: MUDr. Tat’ána Karpianusová; MUDr. Filip Šiška
- University Hospital Hradec Králové; PI: MUDr. Stanislav John
- University Hospital Brno; PI: MUDr. Michal Eid;
MUDr. Štěpán Tuček, Ph.D. - Masaryk Institute of Oncology; PI: MUDr. Peter Grell, Ph.D.
Name
- PREDI-LYNCH; Validated non-invasive liquid biopsy tests for cancer PREDIction in LYNCH Syndrome
Design
- An international, multicentre (29 clinical sites), randomised controlled clinical trial with a non-inferiority design
Diagnosis
- Patients with Lynch syndrome without active cancer
Description
- The aim is to assess whether non-invasive liquid biopsies can safely reduce the frequency of invasive surveillance procedures in LS carriers.
Contact
- Contracting authority: the Oslo University Hospital
- Leading Investigator: Dr. Mev Dominguez-Valentin
Centres in the Czech Republic
- Masaryk Institute of Oncology; PI: MUDr. Vladimír Krass
Name
- ScrePan, Screening for pancreatic cancer in high-risk individuals, NCT06330441
Status
- Active recruitment
Design
- Prospective low-intervention screening clinical trial
Diagnosis
- Population at increased risk of pancreatic cancer
Description
- The aim is to implement the PDAC screening programme nationally, early diagnosis of PDAC in the population of people at high risk of PDAC, identification of diagnostic/prognostic biomarkers, cost-effectiveness analysis of individual screening tests.
Contact
- Contracting authority: the Masaryk Institute of Oncology
- Leading Investigator: MUDr. Peter. Karásek, Ph.D.
Centres in the Czech Republic
- Thomayer University Hospital; PI: doc. MUDr. Pavel Kohout, Ph.D.
- University Hospital Královské Vinohrady; PI: MUDr. Jan Matouš
- Bulovka University Hospital; PI: prof. MUDr. Robert Gürlich, CSc.
- University Hospital Pilsen; PI: MUDr. Václav Hejda
- University Hospital Hradec Králové; PI: MUDr. Petr Vyhnálek, Ph.D.
- St. Anne’s University Hospital in Brno; PI: MUDr. Katarína Glombová
- University Hospital Brno; PI: MUDr. Milan Dastych
- Masaryk Institute of Oncology; PI: MUDr. Peter. Karásek, Ph.D.
- Hospital AGEL Prostějov; PI: MUDr. Mgr. Jaroslav Maceček, Ph.D., MBA
- University Hospital Ostrava; PI: MUDr. Martin Blaho
Planned and upcoming clinical trials
Name
- NeoART; A phase Ib/II platform trial evaluating the safety and activity of neoadjuvant trastuzumab-deruxtecan containing combination therapies for HER2+, resectable esophagogastric adenocarcinoma, 2024-518841-12-00
Design
- Phase Ib/II, prospective, single-arm, open-label, non-randomized, multicenter clinical trial
Diagnosis
- HER2 positive resectable adenocarcinoma of the esophagus and stomach
Description
- The aim is to evaluate the feasibility and safety of various neoadjuvant combination regimens containing T-DXd in patients with HER2-positive, locally advanced, resectable esophagogastric adenocarcinoma (EGA).
Contact
- Sponsor: Frankfurter Institut Für Klinische Krebsforschung IKF GmbH
- Leading Investigator: Prof. Dr. med. Florian Lordick
Centres in the Czech Republic
- Masaryk Institute of Oncology; PI: doc. MUDr. Radka Lordick Obermannová, Ph.D.
- General University Hospital in Prague; PI: doc. MUDr. Michal Vočka, Ph.D.
- University Hospital Hradec Králové; PI: doc. MUDr. Milan Vošmik, Ph.D.
Status
- Germany, recruitment
- Austria, authorized, before recruitment begins
- Czech Republic, awaiting authorisation
Expected launch in the Czech Republic
- Q4/2025
Name
- MyPREDICTION; Multi-omic analysis to PREDICT response and toxicity to chemo-ImmunOtherapy in gastric cancer
Design
- Multicentre cohort study with translational focus
Diagnosis
- Metastatic or unresectable locally advanced gastric cancer (GC) and gastroesophageal junction (GEJ)
Description
- The main objectives of the study are (i) to identify novel biomarkers associated with prognosis and treatment-related adverse events by integrating multiomics data, (ii) to monitor longitudinal changes in circulating biomarkers and their impact on prognosis and treatment-related adverse events, (iii) to perform early health technology assessment (HTA) and develop decision analytic models to assess testing and treatment strategies based on multiomics profiling.
Contact
- Sponsor: Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”-IRST and Verona University Hospital
- Leading Investigator: Dr. Chiara Molinari
Centres in the Czech Republic
- Masaryk Institute of Oncology; PI: doc. MUDr. Radka Lordick Obermannová, Ph.D.
Status
- Applied to the EPPERMED-2025-248 call
Expected launch in the Czech Republic
- xxx
Name
- ODYSSEY; Oligometastatic gastroesophageal aDenocarcinoma Yielding to §perSonalized SurgErY through AI-based predictive model navigation
Design
- Multicentre investigator-initiated academic study as a “pragmatic trial”, single arm, phase II
Diagnosis
- Oligometastatic gastric and gastroesophageal junction carcinoma (OGEAC)
Description
- The primary objective of the study is to validate the clinical benefit (in terms of disease progression-free survival and quality of life) of a multimodal strategy combining systemic therapy with surgery and/or other local ablative therapies in OGEAC and to develop and validate an AI-based predictive model to guide the use of consolidative local therapy in the multidisciplinary management of OGEAC.
Contact
- Contracting authority: University of Verona
- Leading Investigator: prof. Maria Bencivenga
Centres in the Czech Republic
- Masaryk Institute of Oncology; PI: doc. MUDr. Radka Lordick Obermannová, Ph.D.
Status
- Applied to the call HORIZON-MISS-2025-02-CANCER-03
Expected launch in the Czech Republic
- xxx
Completed clinical trials
Name
- GastroPET, Sequential FDG-PET and miRNA as a biomarker of change in preoperative treatment strategy in locally advanced gastric and gastroesophageal junction cancer, a phase II clinical trial (CZE)
Launch
- 1.8.2017
Exit
- 30.11.2024
Design
- Prospective, interventional, non-randomized, open-label phase II with 2 arms according to early metabolic response, 70 patients planned.
Diagnosis
- Resectable GEJ adenocarcinoma (Siewert I-III), clinical stages Ib-IIIc with indication for FOLFOX or FLOT treatment
Description
- The primary objective of the study is to evaluate the predictive value of repeat FDG-PET as a potential biomarker for early change in treatment strategy leading to higher R0 resection rates.
Contact
- Contracting authority: the Masaryk Institute of Oncology
- Leading Investigator: doc. MUDr. Radka Lordick Obermannová, Ph.D.
Centres
- Masaryk Institute of Oncology; PI: doc. MUDr. Radka Lordick Obermannová, Ph.D
- General University Hospital Prague; PI: doc. MUDr. Milada Zemanová, Ph.D.
- University Hospital Olomouc; PI: doc. MUDr. Hana Studentová, Ph.D.
Results/practical impact
- The results confirm the feasibility, safety of the algorithm and the high rate of R0 resections (89% in both arms).
- Practical implications for patients: if the tumor is metabolically unresponsive after the first cycle of chemotherapy (CHT), an early change to CHT+RT may preserve a high percentage of R0 resections without an apparent increase in perioperative risks, instead of ineffective continuation of CHT alone.
Publications
- PET/CT-tailored treatment of locally advanced oesophago-gastric junction adenocarcinoma: a report on the feasibility of the multicenter GastroPET study.Obermannova R, Selingerova I, Rehak Z, Jedlicka V, Slavik M, Fabian P, Novotny I, Zemanova M, Studentova H, Grell P, Zdrazilova Dubska L, Demlova R, Harustiak T, Hejnova R, Kiss I, Vyzula R. Ther Adv Med Oncol. 2022 Jan 5;13:17588359211065153. doi: 10.1177/17588359211065153. eCollection 2021.PMID: 35035533
Follow-up projects
- GastroPET II follow-up study – non-interventional follow-up of secondary endpoints in the population of patients enrolled in the GastroPET study, specifically the predictive values of PET for disease free survival (DFS) and overall survival (OS) in the individual arms defined by the GastroPET study protocol.
How to Get Involved and Contact
If you are interested in involving your institution in a specific ongoing clinical trial coordinated by the CZECRIN | ONCO network, please fill in the following form. Based on the information you provide, a study coordinator will contact you with details about the possibilities of cooperation.
Are you a center interested in joining an ongoing study?
Are you interested in involving your site in a specific ongoing clinical trial coordinated by the CZECRIN | ONCO network? Please fill in the following form. Based on the information you provide, a study coordinator will contact you with details about the possibilities of cooperation.
Are you a patient interested in participating in an ongoing study?
If you are interested in participating as a patient in a cancer clinical trial, please fill out the following form. Your interest will be forwarded to the CZECRIN | ONCO coordinator, who will contact you about suitable participation options.
PREPARING
Follow us on the networks!
